Kdt Ventures

Founders see chance to build start-ups from university IP, with clinical infrastructure already in place from local institutions

BioCentury’s Venture Report also includes fundings for Nuclera, TenNor, Shift, Tolerance and Sunbird

Plus: Glaub, Enright become CEO, chair at CuraSen and updates from Volastra, Essential Pharma and Transpire

Plus: Surge raises $32M B round, Keytruda meets in cervical cancer and more

Plus Apposite Capital raises third fund and updates from Biogen, Avidity, Vertex-CRISPR and more

Plus Cytokinetics prices $450M note deal and updates from NRx and Regard

Northpond and Pfizer, Taiho VC affiliates back $65M series A for newco exploring largely uncharted area of tumor immunotherapy biology

Biocon partners with Serum Institute, plus Santé’s $260M fund, IASO Bio’s $108M series C, Everest in $12M renal deal and more

Emerging Company Profile: Xilis raises $70M led by Mubadala to advance tech for cancer drug development, treatment selection

Singapore-based Temasek will supply $200 million to G2 Management Co. Inc. to foster the development of therapies from the University of Pennsylvania's Gene Therapy Program, led by James Wilson.